Phase II Single Dose, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy of Three Dose Levels of AIN457 in Patients With Chronic Plaque-Type Psoriasis
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 02 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Oct 2009 New trial record.